A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: immediate daratumumab + VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethnic minorities, including Black or African American, with newly diagnosed AL amyloidosis treated with D-VCd (cohort 2).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alexis Walker
- Alison Johnson
- Andrea Brennan
- Armand Russo, MD
- Beverly Drucker, MD, PhD
- Catherine Wei, MD
- D. Barry Boyd, MD, MS
- David Witt, MD
- Emily Kopas, APRN, OCN
- Erica Stevens
- Francesca Montanari, MD
- Jade Vanacore
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Jose Morales-Marin
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- Leena Rahmat
- M. Sung Lee, MD
- Madeline Santiago
- Natalia Neparidze, MD
- Neal Fischbach, MD
- Noffar Bar, MD
- Renee Moye
- Sabrina Browning, MD
- Sara Anastasio, RN
- Stephanie Paine, APRN
- Stuart Seropian, MD
- Sudhanshu Mulay, MD
- Syed Ali
- Syed Ali
- Syed Bilgrami, MBBS
- Tara Anderson
- Terri Parker, MD
- Vidya Kesavan
- Virginia Syombathy
- Last Updated04/19/2024
- Study HIC#2000034301